{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LY2835219", "query": { "intervention": "LY2835219" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LY2835219&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:01:48.259Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02102490", "title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2014-06-10", "completion_date": "2018-10-22", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 27, "location_summary": "Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102490" }, { "nct_id": "NCT01913314", "title": "A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "[^14C]-LY2835219", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2013-08", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01913314" }, { "nct_id": "NCT05169567", "title": "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasm", "Neoplasm Metastasis" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2022-03-11", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 60, "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169567" }, { "nct_id": "NCT04469764", "title": "Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 32, "start_date": "2020-10-16", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469764" }, { "nct_id": "NCT04010357", "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Large Cell Neuroendocrine Carcinoma of the Lung", "Extrapulmonary Small Cell Carcinoma" ], "interventions": [ { "name": "Abemaciclib,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 14, "start_date": "2020-01-13", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04010357" }, { "nct_id": "NCT02846987", "title": "Study of Abemaciclib in Dedifferentiated Liposarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2016-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846987" }, { "nct_id": "NCT02688088", "title": "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2016-03-08", "completion_date": "2021-01-06", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 5, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688088" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT06179303", "title": "Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Locally Advanced Unresectable HER2-Negative Breast Carcinoma", "Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Fluorine F 18 Fluoro Furanyl Norprogesterone", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Gonadotropin-releasing Hormone Analog", "type": "BIOLOGICAL" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Therapeutic Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-07-22", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 2, "location_summary": "St Louis, Missouri • Seattle, Washington", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179303" }, { "nct_id": "NCT02791334", "title": "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Microsatellite Instability-High (MSI-H) Solid Tumors", "Cutaneous Melanoma", "Pancreatic Cancer", "Breast Cancer (HR+HER2-)" ], "interventions": [ { "name": "LY3300054", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Merestinib", "type": "DRUG" }, { "name": "LY3321367", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2016-06-29", "completion_date": "2024-06-27", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-09-02T21:01:48.259Z", "location_count": 3, "location_summary": "Nashville, Tennessee • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02791334" } ] }